Sutent

Gastrointestinal Stromal Tumors, Renal Cell Carcinoma
Treatment
8 Active Studies for Sutent

What is Sutent

SunitinibThe Generic name of this drug
Treatment SummarySunitinib is a medication used to treat certain types of cancer, including renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor. It works by blocking several types of receptors that stimulate cell growth in the body. It is taken orally and works by targeting multiple receptor tyrosine kinases, including platelet-derived growth factor receptors, vascular endothelial growth factor receptors, and KIT (CD117), which is responsible for most GISTs. It also blocks other receptor tyrosine kinases such as RET, CSF-1R, and flt3.
Sutentis the brand name
image of different drug pills on a surface
Sutent Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sutent
Sunitinib
2006
26

Effectiveness

How Sutent Affects PatientsSunitinib is a medication taken by mouth that works by blocking certain proteins (known as receptor tyrosine kinases) that help regulate cell growth. It was approved by the FDA on January 26, 2006.
How Sutent works in the bodySunitinib is a drug that helps prevent the growth of tumors, abnormal blood vessel formation, and cancer spreading. Sunitinib works by blocking certain receptor tyrosine kinases (RTKs). These RTKs are responsible for growth factors like platelet-derived and vascular endothelial, stem cell factor, FMS-like tyrosine kinase, colony stimulating factor, and glial cell-line derived neurotrophic factor. Sunitinib has been shown to block these RTKs in biochemical, cellular, and cell proliferation assays. It also has a primary metabolite that has similar effects.

When to interrupt dosage

The prescribed amount of Sutent is contingent upon the recognized state, including unresectable, locally advanced Pancreatic Neuroendocrine Tumors, metastatic Pancreatic Neuroendocrine Tumors and Gastrointestinal Stromal Tumors. The dosage fluctuates, as per the method of delivery featured in the table beneath.
Condition
Dosage
Administration
Renal Cell Carcinoma
12.5 mg, , 50.0 mg, 25.0 mg, 37.5 mg
Oral, Capsule - Oral, , Capsule
Gastrointestinal Stromal Tumors
12.5 mg, , 50.0 mg, 25.0 mg, 37.5 mg
Oral, Capsule - Oral, , Capsule

Warnings

There are 20 known major drug interactions with Sutent.
Common Sutent Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Sunitinib is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Sunitinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Sunitinib is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Sunitinib is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Sunitinib is combined with Antilymphocyte immunoglobulin (horse).
Sutent Toxicity & Overdose RiskThe highest dose of this drug that can be given to rats, mice, dogs, and non-human primates, without causing toxicity is more than 500mg/kg for rats, mice, and dogs, and more than 1200mg/kg for non-human primates.
image of a doctor in a lab doing drug, clinical research

Sutent Novel Uses: Which Conditions Have a Clinical Trial Featuring Sutent?

114 active trials are assessing the potential of Sutent in managing unresectable, locally advanced Pancreatic Neuroendocrine Tumors, metastatic Pancreatic Neuroendocrine Tumors and Soft Tissue Sarcoma.
Condition
Clinical Trials
Trial Phases
Gastrointestinal Stromal Tumors
3 Actively Recruiting
Phase 2, Phase 1
Renal Cell Carcinoma
5 Actively Recruiting
Phase 1, Phase 2

Sutent Reviews: What are patients saying about Sutent?

5Patient Review
3/7/2015
Sutent for Cancer Involving the Kidney Cells
Sutent has been an absolute lifesaver for me. I was diagnosed with stage IV metastatic renal cell carcinoma about 18 months ago, and since then the tumors have either disappeared or shrunk to very small sizes. The side effects are unpleasant but manageable, and I would highly recommend this drug to anyone in a similar situation.
5Patient Review
4/29/2014
Sutent for Cancer Involving the Kidney Cells
Though there are some not-so-great side effects that come along with this treatment, I can deal with them. I've been on it for four years now and so far it seems to be working; my next scan is in a week.
5Patient Review
11/25/2015
Sutent for Cancer Involving the Kidney Cells
I've been on Sutent for 4 1/2 years now and it's helped a lot. I originally had 9 nodules in my lungs, but they're all gone now. There are some side effects that come with the medication, but it's still working well overall. I know I'll have cancer until it's gone, but this drug has helped me stay alive and fighting.
5Patient Review
4/10/2015
Sutent for Cancer Involving the Kidney Cells
I had my right kidney removed in 2011, and a PET scan in 2012 showed 4 small tumors. I started taking sutent in February of 2012, at a dosage of 50mg for 2 cycles, 37.5mg for 2 cycles, 25mg for 2 cycles, and 12.5mg for 2 cycles. The PET scan showed no RCC cells present. The side effects were tolerable and I haven't had any major problems.
5Patient Review
3/11/2014
Sutent for Cancer Involving the Kidney Cells
This treatment was great and I would recommend it to others.
4.3Patient Review
5/18/2019
Sutent for renal cell carcinoma adjuvant therapy following nephrectomy
After my right kidney was removed in September 2018, I started taking 50mg of Sutent. Unfortunately, I had to stop after two weeks due to serious side effects. The dosage was then reduced to 37.5 mg and I've been on this for six months, taking a break every other week. Side effects have included a red rash on my scalp, diarrhea, fatigue, and everything tasting salty. Bumps have also appeared on my tongue that are quite sore. Thankfully, treatment is ending on October 24th 2019 and tests show no cancer anywhere else in my body.
4Patient Review
12/20/2013
Sutent for Cancer Involving the Kidney Cells
I've been taking Sutent 50mg for three months as part of my treatment for renal cancer with metastases in the colon and brain. The side effects are significant fatigue, loss of muscle tone, loss of appetite, decreased sense of taste, rectal bleeding, and dry skin. However, the benefits are worth it because my brain tumor has completely disappeared in two months. In other words, this medication has saved my life even though it's tough to deal with on a daily basis.
4Patient Review
11/28/2019
Sutent for Cancer Involving the Kidney Cells
I've had a few small brain tumors removed since starting treatment with Sutent for renal cell carcinoma.
4Patient Review
2/13/2014
Sutent for Cancer Involving the Kidney Cells
I didn't have much of an appetite while taking this medication, and the food I did eat tasted bland.
3.3Patient Review
8/7/2014
Sutent for Cancer Involving the Kidney Cells
I'm only on my third week of this medication, and I've already experienced bad bloating, fatigue, and a sleep disorder.
3.3Patient Review
12/26/2012
Sutent for Cancer Involving the Kidney Cells
I experienced a lot of unpleasant side effects while taking this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sutent

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long do cancer patients live with Sutent?

"Sutent resulted in a progression-free survival of 24.1 weeks compared to 6.0 weeks for placebo. For patients specifically with pancreatic neuroendocrine tumors, Sutent resulted in a 10.2 month progression-free survival while placebo resulted in only a 5.4 month progression-free survival."

Answered by AI

What is the drug Sutent used for?

"SUTENT can be used:

-To treat adults with advanced kidney cancer

-To treat adults with GIST that cannot be surgically removed, or has spread to other parts of the body

SUTENT is used to treat advanced pancreatic neuroendocrine tumors and kidney cancer in adults. It can also be used to treat gastrointestinal stromal tumors (GIST) that cannot be surgically removed, or have spread to other parts of the body."

Answered by AI

Does Sutent cure cancer?

"SUTENT slows cancer growth and may prevent cancer cells from spreading by binding to receptors on the cells' surface. SUTENT is not a cure, and not all patients will experience the same results."

Answered by AI

What are the side effects of Sutent?

"Tiredness or weakness, diarrhea, mouth pain, nausea/vomiting, loss of appetite, indigestion, stomach pain, and blisters or rash are all side effects that you and your doctor may be able to manage."

Answered by AI

Is Sutent a chemotherapy?

"Sutent is a cancer treatment that works by inhibiting receptors on the surface of some cells. It is considered a targeted treatment, rather than a traditional chemotherapy drug."

Answered by AI

Clinical Trials for Sutent

Image of City of Hope Medical Center in Duarte, United States.

RP2 + Tivozanib for Kidney Cancer

18+
All Sexes
Duarte, CA
This phase II trial tests the effect of RP2 and tivozanib in treating patients with renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing, spreading, or getting worse (progressive) after receiving immunotherapy with immune checkpoint inhibitors (ICIs). RP2 is a herpes simplex virus (a viral infection commonly known as the "cold sore virus") that has been changed to infect and destroy tumor cells and to activate (turn on) the human immune system to attack the tumor cells. Tivozanib hydrochloride blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Tivozanib hydrochloride is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Giving RP2 and tivozanib may be safe, tolerable, and/or effective in treating patients with metastatic renal cell cancer that has progressed after receiving immunotherapy with ICIs.
Phase 2
Waitlist Available
City of Hope Medical Center (+1 Sites)Charles B Nguyen
Have you considered Sutent clinical trials? We made a collection of clinical trials featuring Sutent, we think they might fit your search criteria.Go to Trials
Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Nivolumab + Ipilimumab for Rare Cancers

18+
All Sexes
Birmingham, AL
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer \[NPC\], and squamous cell carcinoma of the head and neck \[SCCHN\]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03/20/2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. Intrahepatic cholangiocarcinoma (closed to accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (closed to accrual) 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual) 16. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non seminomatous tumor C) Teratoma with malignant transformation (closed to accrual) 17. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis (closed to accrual) 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07/27/2018) 21. Odontogenic malignant tumors 22. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) 23. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) 24. Pheochromocytoma, malignant (closed to accrual) 25. Paraganglioma (closed to accrual 11/29/2018) 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex (closed to accrual) 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09/19/2018) 29. Malignant giant cell tumors 30. Chordoma (closed to accrual 11/29/2018) 31. Adrenal cortical tumors (closed to accrual 06/27/2018) 32. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12/22/2017) 33. Not Otherwise Categorized (NOC) Rare Tumors \[To obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.org\] (closed to accrual 03/15/2019) 34. Adenoid cystic carcinoma (closed to accrual 02/06/2018) 35. Vulvar cancer (closed to accrual) 36. MetaPLASTIC carcinoma (of the breast) (closed to accrual) 37. Gastrointestinal stromal tumor (GIST) (closed to accrual 09/26/2018) 38. Perivascular epithelioid cell tumor (PEComa) 39. Apocrine tumors/extramammary Paget's disease (closed to accrual) 40. Peritoneal mesothelioma 41. Basal cell carcinoma (temporarily closed to accrual 04/29/2020) 42. Clear cell cervical cancer 43. Esthenioneuroblastoma (closed to accrual) 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell endometrial cancer 46. Clear cell ovarian cancer (closed to accrual) 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor \[PNET\] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 53). Small cell lung cancer is not eligible (closed to accrual) 53. Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC)
Phase 2
Waitlist Available
University of Alabama at Birmingham Cancer Center (+99 Sites)Sandip P Patel
Image of Moffitt Cancer Center-International Plaza in Tampa, United States.

Ziv-aflibercept + Pembrolizumab for Cancer

18+
All Sexes
Tampa, FL
This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Ziv-afibercept works by decreasing blood and nutrient supply to the tumor, which may result in shrinking the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ziv-aflibercept together with pembrolizumab may be a better treatment for patients with advanced solid tumors.
Phase 1
Waitlist Available
Moffitt Cancer Center-International Plaza (+8 Sites)Frank S Hodi
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security